Cancer therapeutics: targeting the dark side of Myc

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The Myc oncoprotein is a critical regulator of tumorigenesis in many human cancers.
• Inhibition of Myc has been experimentally shown to halt tumor cell growth and proliferation.

Purpose of the Study:

• To review recent advances in understanding Myc's function as a transcription factor.
• To summarize progress in drug development targeting Myc.
• To discuss future anti-Myc therapeutic strategies.

Main Methods:

• Review of experimental evidence on Myc function and inhibition.
• Analysis of key protein interactions and target gene regulation by Myc.
• Survey of current and emerging anti-Myc drug development (oligonucleotides, porphyrins, siRNA).

Main Results:

• Myc's role as a transcription factor in cancer is complex, involving specific protein interactions and target gene regulation.
• Various drug development strategies are emerging to inhibit Myc's expression and/or function.
• Targeting Myc presents a promising avenue for novel cancer therapies.

Conclusions:

• Understanding Myc's intricate functions is crucial for developing effective cancer treatments.
• Novel therapeutic agents targeting Myc have the potential to significantly impact cancer therapy.
• Future strategies will focus on inhibiting Myc at both expression and functional levels.